EDITAS MEDICINE, INC. Contracts Revenue (Deprecated 2018-01-31)
EDITAS MEDICINE, INC. (EDIT) reported Contracts Revenue (Deprecated 2018-01-31) of $3.67 million for the 3-month period ending 2017-12-31, per its 10-K filed 2018-03-08.
Discontinued › Income Statement › Other Income
us-gaap:ContractsRevenue · last filed 2018-03-08
- EDITAS MEDICINE, INC. contracts revenue (deprecated 2018-01-31) for the quarter ending 2017-12-31 was $3.67M, a 308.35% increase year-over-year.
- EDITAS MEDICINE, INC. contracts revenue (deprecated 2018-01-31) for the quarter ending 2017-09-30 was $6.28M, a 553.01% increase year-over-year.
- EDITAS MEDICINE, INC. contracts revenue (deprecated 2018-01-31) for the quarter ending 2017-06-30 was $3.10M, a 8.59% decline year-over-year.
- EDITAS MEDICINE, INC. contracts revenue (deprecated 2018-01-31) for the quarter ending 2017-03-31 was $682.00K, a 15.28% decline year-over-year.
- EDITAS MEDICINE, INC. contracts revenue (deprecated 2018-01-31) for fiscal 2017 was $13.73M, a 126.80% increase from fiscal 2016.
- EDITAS MEDICINE, INC. contracts revenue (deprecated 2018-01-31) for fiscal 2016 was $6.05M, a 271.58% increase from fiscal 2015.
- EDITAS MEDICINE, INC. contracts revenue (deprecated 2018-01-31) for fiscal 2015 was $1.63M.
| Period end | Contracts Revenue (Deprecated 2018-01-31) 3 month | Contracts Revenue (Deprecated 2018-01-31) 6 month | Contracts Revenue (Deprecated 2018-01-31) 9 month | Contracts Revenue (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|
| 2017-12-31 | $3.67M 10-K · filed 2018-03-08 | $9.95M derived: sum of 2 quarters · filed 2018-03-08 | $13.05M derived: sum of 3 quarters · filed 2018-03-08 | $13.73M 10-K · filed 2018-03-08 |
| 2017-09-30 | $6.28M 10-K · filed 2018-03-08 | $9.38M derived: sum of 2 quarters · filed 2018-03-08 | $10.06M 10-Q · filed 2017-11-08 | $10.96M derived: sum of 4 quarters · filed 2018-03-08 |
| 2017-06-30 | $3.10M 10-K · filed 2018-03-08 | $3.78M 10-Q · filed 2017-08-09 | $4.68M derived: sum of 3 quarters · filed 2018-03-08 | $5.64M derived: sum of 4 quarters · filed 2018-03-08 |
| 2017-03-31 | $682.00K 10-K · filed 2018-03-08 | $1.58M derived: sum of 2 quarters · filed 2018-03-08 | $2.54M derived: sum of 3 quarters · filed 2018-03-08 | $5.93M derived: sum of 4 quarters · filed 2018-03-08 |
| 2016-12-31 | $898.00K 10-K · filed 2018-03-08 | $1.86M derived: sum of 2 quarters · filed 2018-03-08 | $5.25M derived: sum of 3 quarters · filed 2018-03-08 | $6.05M 10-K · filed 2018-03-08 |
| 2016-09-30 | $962.00K 10-K · filed 2018-03-08 | $4.35M derived: sum of 2 quarters · filed 2018-03-08 | $5.16M 10-Q · filed 2017-11-08 | $5.95M derived: sum of 4 quarters · filed 2018-03-08 |
| 2016-06-30 | $3.39M 10-K · filed 2018-03-08 | $4.19M 10-Q · filed 2017-08-09 | $4.99M derived: sum of 3 quarters · filed 2018-03-08 | $5.66M derived: sum of 4 quarters · filed 2018-03-08 |
| 2016-03-31 | $805.00K 10-K · filed 2018-03-08 | $1.60M derived: sum of 2 quarters · filed 2018-03-08 | $2.27M derived: sum of 3 quarters · filed 2018-03-08 | $2.43M derived: sum of 4 quarters · filed 2018-03-08 |
| 2015-12-31 | $792.00K 10-K · filed 2017-03-03 | $1.46M derived: sum of 2 quarters · filed 2017-03-03 | $1.63M derived: sum of 3 quarters · filed 2017-03-03 | $1.63M 10-K · filed 2018-03-08 |
| 2015-09-30 | $670.00K 10-K · filed 2017-03-03 | $837.00K derived: sum of 2 quarters · filed 2017-03-03 | $837.00K 10-Q · filed 2016-11-09 | |
| 2015-06-30 | $167.00K 10-K · filed 2017-03-03 | $167.00K 10-Q · filed 2016-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |